View More View Less
  • 1 University of Tehran, Iran
  • | 2 Nuclear Agriculture Research School, Nuclear Science and Technology Research Institute, Iran
  • | 3 Razi Vaccine and Serum Research Institute, Iran
  • | 4 International Atomic Energy Agency (IAEA), VIC, Austria
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Avian influenza (AI) A subtype H9N2 virus belongs to Orthomyxoviridae family and causes low-pathogenic disease AI. The use of gamma-irradiated viral antigens has been developed in the production of effective vaccines. In this research, LPAIV H9N2 strain, A/Chicken/IRN/Ghazvin/2001, was multiplied on SPF eggs and irradiated by a Nordian gamma cell instrument. Irradiated and non-irradiated AI virus (AIV) samples were titrated by EID50 method and hemagglutinin (HA) antigen was analyzed by HA test as the WHO pattern method. Infectivity of irradiated virus was determined by egg inoculation method during four blind cultures. The results showed that after increasing the dose of gamma radiation, virus titer gradually decreased. D10 value and optimum dose for complete virus inactivation were calculated by dose/response curve, 3.36 and 29.52 kGy, respectively. In addition, HA antigenicity of gamma-irradiated virus samples from 0 to 30 kGy was not changed. The results of safety test for gamma-irradiated AIV samples showed complete inactivation with gamma ray doses 30 and 35 kGy, without any multiplication on eggs after four blind cultures. According to the results of HA antigen assay and safety test, the gamma-irradiated and complete inactivated AIV subtype H9N2 is a good candidate as an inactivated immunogenic agent for poultry vaccination.

  • 1.

    OIE Terrestrial Manual: Avian influenza. Infection with avian influenza virus. World Organization for Animal Health, Chapter 2.3.4, 2015, p. 1.

    • Search Google Scholar
    • Export Citation
  • 2.

    Anvar, E., Hosseini, S. M., Tavasoti-Khiri, M., Mazaheri, V., Fazaei, K., Shabani, M.: Serological survey of avian influenza (H9N2) among different occupational groups in Tehran and Ghazvin provinces in IR Iran. Jundishapure J Microbiol 6, e5441 (2013).

    • Search Google Scholar
    • Export Citation
  • 3.

    Lu, X., Renshaw, M., Tumpey, T. M., Kelly, G. D., Hu-Primmer, J., Katz, J. M.: Immunity to influenza A H9N2 viruses induced by infection and vaccination. J Virol 75, 48964901 (2001).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Naeem, K., Ullah, A., Manvell, R. J., Alexander, D. J.: Avian influenza A subtype H9N2 in poultry in Pakistan. Vet Rec 145, 560 (1999).

  • 5.

    Alexander, D. J.: Phylogenetic analysis of influenza A virus of H9 hemagglutinin subtype. Avian Pathol 29, 353360 (2000).

  • 6.

    Reed, L. J., Muench, H.: A simple method of estimating 50% endpoints. Am J Hyg 27, 493497 (1938).

  • 7.

    WHO: Laboratory Procedures. Serological Detection of Avian Influenza A (H7N9) Virus Infections by Turkey Haemagglutination-Inhibition Assay. WHO Collaborating Center for Reference and Research on Influenza Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, 2013. Available at http://www.who.int/influenza/gisrs_laboratory/cnic_serological_diagnosis_hai_a_h7n9.pdf

    • Search Google Scholar
    • Export Citation
  • 8.

    Larghi, O. P., Nebel, A. E.: Rabies virus inactivation by binary ethylenimine: New method for inactivated vaccine production. J Clin Microbiol 11, 120122 (1980).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Amanna, I. J., Raue, H. P., Slifka, M. K.: Development of a new hydrogen peroxide-based vaccine platform. Nat Med 18, 974979 (2012).

  • 10.

    Martin, S. S., Bakken, R. R., Lind, C. M., Garcia, P., Jenkins, E., Glass, P. J., Parker, M. D., Hart, M. K., Fine, D. L.: Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine 28, 10311040 (2010).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Alsharifi, M., Mullbacher, A.: The gamma-irradiated influenza vaccine and the prospect of producing safe vaccines in general. Immunol Cell Biol 88, 103104 (2010).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Budowsky, E. I., Bresler, S. E., Friedman, E. A., Zheleznova, N. V.: Principles of selective inactivation of viral genome. I. UV-induced inactivation of influenza virus. Arch Virol 68, 239247 (1981).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Nims, R. W., Plavsic, M.: Polyomavirus inactivation – A review. Biologicals 41, 6370 (2012).

  • 14.

    Stauffer, F., El-Bacha, T., Da-Poian, A. T.: Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov 1, 291296 (2006).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Metz, B., Kersten, G. F., Hoogerhout, P., Brugghe, H. F., Timmermans, H. A., De-Jong, A., Meiring, H., Ten-Hove, J., Hennink, W. E., Crommelin, D. J., Jiskoot, W.: Identification of formaldehyde-induced modifications in proteins: Reactions with model peptides. J Biol Chem 279, 62356243 (2004).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Metz, B., Kersten, G. F., Baart, G. J., De-Jong, A., Meiring, H., Ten-Hove, J., Van-Steenbergen, M. J., Hennink, W. E., Crommelin, D. J., Jiskoot, W.: Identification of formaldehyde-induced modifications in proteins: Reactions with insulin. Bioconjug Chem 17, 815822 (2006).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Thaysen-Andersen, M., Jorgensen, S. B., Wilhelmsen, E. S., Petersen, J. W., Hojrup, P.: Investigation of the detoxification mechanism of formaldehyde-treated tetanus toxin. Vaccine 25, 22132227 (2007).

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Nunnally, B. K., Turula, V. E., Sitrin, R. D.: Vaccine analysis: Strategies, principles, and control. In Sanders, B., Koldijk, M., Schuitemaker, H. (ed): Inactivated Viral Vaccine, Chapter 2. Springer-Verlag, Berlin/Heidelberg, 2015. Available at http://www.springer.com/978-3-662-45023-9

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol. International Agency for Research on Cancer, Lyon, 2006, p. 88. Available at http://monographs.iarc.fr/ENG/Monographs/vol88/index.php

    • Search Google Scholar
    • Export Citation
  • 20.

    National Cancer Institute [NIH]: Formaldehyde and Cancer Risk, 2017. Available at https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/formaldehyde/formaldehyde-fact-sheet

    • Search Google Scholar
    • Export Citation
  • 21.

    Vasfi-Marandi, M., Bozorgmehrifard, M. H., Hashemzadeh, M.: Efficacy of inactivated H9N2 avian influenza vaccine against non-highly pathogenic A/Chicken/Iran/ZMT-173/1999 infection. Arch Razi Inst 53, 2326 (2002).

    • Search Google Scholar
    • Export Citation
  • 22.

    Tavakkoli, H., Asasi, K., Mohammadi, A.: Effectiveness of two H9N2 low pathogenic avian influenza conventional inactivated oil emulsion vaccines on H9N2 viral replication and shedding in broiler chickens. Iran J Vet Res 12, 36 (2011).

    • Search Google Scholar
    • Export Citation

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
sumbission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Online subsscription: 652 EUR / 812 USD
Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Feb 2021 38 0 0
Mar 2021 17 0 0
Apr 2021 13 0 0
May 2021 33 0 0
Jun 2021 16 0 0
Jul 2021 6 0 0
Aug 2021 0 0 0